TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01687478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT00002865
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002865
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00440024
Drug: Dove Facial Moisturizer
Normalized name: Dove DermaSeries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizing cream - Dove facial moisturizer with SPF 15
Study: NCT00002865
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002865
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04493281
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous formulation
Study: NCT01007942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
Study: NCT01533766
Drug: CombiflexOmega
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously over 5 days infusion
Study: NCT01081535
Drug: ketorolac, fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous PCA
Study: NCT04549935
Drug: Topical Prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care topical drop treatment
Study: NCT03300544
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03300544
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03300544
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00051987
Drug: VELCADE TM (bortezomib) for Injection, or PS-341
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03393806
Drug: GSK3772847
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
Study: NCT03393806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially sourced sterile normal saline will be provided as Placebo
Study: NCT02649985
Drug: [F-18]PBR06
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical
Study: NCT02649985
Drug: [C-11]PBR28
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical
Study: NCT01675661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
Study: NCT02435095
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Study: NCT02435095
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Study: NCT01050608
Drug: 62% ethanol based hand cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDC based guidelines with regard to utilization in the health care environment the nest
Study: NCT03806374
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl
Study: NCT02670954
Drug: Dexmedetomidine, tramadol and flurbiprofen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02670954
Drug: tramadol and flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006055
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04269538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC dosing
Study: NCT00977379
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
Study: NCT00977379
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
Study: NCT02118090
Drug: DHA-PP
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
Study: NCT00787059
Drug: Ad5.hAC6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
Study: NCT00556400
Drug: Placebo - sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04561375
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 µg tablet of sublingual sufentanil
Study: NCT04561375
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 µg fentanyl
Study: NCT01386151
Drug: Keratinocyte Growth factor
Normalized name: Keratinocyte growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
Study: NCT01386151
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal (0.9%) saline will be used as a placebo.
Study: NCT00654966
Drug: Urotensine II
Approvals — FDA: no, EMA: no, PMDA: no
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Study: NCT01359969
Drug: rhC1INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
Study: NCT00593736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
Study: NCT01268332
Drug: Non-medicated Intravaginal Ring
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
Study: NCT01123135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03825341
Drug: Hydroxyurea Oral Capsule
Normalized name: hydroxyurea Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
Study: NCT00057421
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002608
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01067235
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
Study: NCT00138970
Drug: Zenapax®, CellCept® and prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00138970
Drug: Sandimmun Neoral®, CellCept® and prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02595749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00918840
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Study: NCT00002883
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01716689
Drug: oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg daily
Study: NCT04260438
Drug: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fed condition
Study: NCT04260438
Drug: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fed condition
Study: NCT04260438
Drug: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fed condition
Study: NCT00106392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00405886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets, duration: 16 weeks
Study: NCT00742924
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01047501
Drug: AMR101 (ethyl icosapentate) - 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
Study: NCT01047501
Drug: AMR101 (ethyl icosapentate) - 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
Study: NCT01047501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 capsules/day for 12 weeks
Study: NCT03342690
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions.
Study: NCT00742924
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00742924
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00742924
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT05537194
Drug: dihydropyridine calcium channel inhibitors use
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of dihydropyridine calcium channel inhibitors
Study: NCT01762930
Drug: Shanchol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
Study: NCT02272634
Drug: YPL-001 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily \[BID\]
Study: NCT02272634
Drug: YPL-001 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily \[BID\]
Study: NCT02272634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily \[BID\]
Study: NCT03821870
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second line treatment based on drug sensitivity analysis
Study: NCT02737748
Drug: TWB-103 Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Study: NCT02737748
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Study: NCT02196701
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate was provided as 2.5 mg tablets for oral administration.
Study: NCT00643565
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT01283594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White-coated, modified-oval placebo tablets.
Study: NCT01283594
Drug: Levodopa (L-dopa)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
Study: NCT04373044
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Po
Study: NCT01704794
Drug: Folic Acid + Paludrine + Jobelyn (250mg)
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard routine drugs for treatment of SCD with 250mg Jobelyn
Study: NCT03399292
Drug: Cationorm MD sine eye drops
Normalized name: tetrahydrozoline hydrochloride Ophthalmic Solution [Eye-Sine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: studyparticipants receive lipidbased eye drops once only in the study eye
Study: NCT02755155
Drug: Human serum albumin infusion 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 15mL/kg of bodyweight over 24h/day
Study: NCT02755155
Drug: Human serum albumin infusion 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
Study: NCT01177410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules once daily for 12 weeks
Study: NCT01056575
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 100mg tablet, twice daily
Study: NCT01688570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
Study: NCT03809988
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (letrozole or fulvestrant)
Study: NCT04559971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride for s.c. injection
Study: NCT01099527
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose escalation of capecitabine, everolimus
Study: NCT01197755
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT00620659
Drug: Comparator: MK0249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
Study: NCT00620659
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
Study: NCT04428333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline
Study: NCT04428333
Drug: Fluorouracil (5FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil
Study: NCT00658645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated tablets, orally, 12 weeks
Study: NCT03038594
Drug: 0.09% Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01196676
Drug: AZD4451
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Study: NCT01196676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Study: NCT00278889
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous infusion
Study: NCT02171494
Drug: BMS Coumadin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00042458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
Study: NCT02040779
Drug: Placebo breath-actuated inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
Study: NCT02860221
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03265288
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
Study: NCT03047798
Drug: Mouthrinse
Normalized name: NaFrinse 0.2% Mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.
Study: NCT04059458
Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
Study: NCT00367458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be administered placebo
Study: NCT00866658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT00866658
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea if given, to be continued at a stable dose.
Study: NCT02390687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study: NCT00742066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose tablet orally
Study: NCT00824616
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
Study: NCT00824616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken 3 times daily.
Study: NCT00577395
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet once a month for 12 months
Study: NCT03427502
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
Study: NCT03427502
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline